The most substantial problem in cancer care is that toxic treatments are administered
without knowing the benefits to individuals. We develop diagnostic tools that personalize
cancer treatments. Our proprietary machine learning algorithm is capable of scouring
large genomic databases to identify patterns in the molecular features of cancers that
predict survival. This has enabled us to rapidly develop nine tests for clinical decisionmaking,
including our lead product, Thyroid GuidePx – set to launch by the end of 2021.
